Long-Term Follow-Up of Low-Dose IL-2 After Heart Attack
Treatments studied
Part of Heart & circulation clinical trials.
This study is checking on people who finished a previous trial (IVORY) that tested a low-dose treatment called IL-2 for reducing inflammation after a heart attack. It will see how they are doing over time and if the treatment helped their heart health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You took part in the IVORY study and finished the full treatment (either low-dose IL-2 or placebo).
- You attended your last scheduled visit for the IVORY study.
- You agreed to be contacted about future research.
- You were not taken out of the IVORY study early for any reason.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a low dose of a natural immune-boosting protein (IL-2) given after heart bypass surgery can help reduce heart damage. The treatment aims to activate special immune cells that protect heart tissue.
This trial is a long-term check-in for people who survived a heart attack and already took part in an earlier study through a 1-year follow-up. The goal is to learn what happens over time after the heart attack and how participants are doing.
This study follows people who had a heart-related side effect from immunotherapy and are now ready for rehab. It aims to better understand recovery and guide treatment.
This study looks at a molecule called OR6A2 on certain immune cells (monocytes) in people who have had a heart attack treated with a stent. It aims to see if this molecule is linked to heart recovery and future heart problems.
This trial tests whether giving IV ferric carboxymaltose can lower the risk of death and heart complications after a recent heart attack, and improve quality of life. It is for adults with low iron levels and specific heart/health risk factors identified soon after their heart attack.
This study follows up with people who previously took part in a clinical trial testing an experimental gene therapy for critical limb ischemia (severe leg pain or sores due to blocked arteries). It aims to see how well the treatment works over time. If you were in that earlier trial and received at least one dose, joining this follow-up could help researchers learn more about the therapy's lasting effects.
Hear when a new Acute Coronary Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.